Elicio Therapeutics, Inc. (ELTX)

Market Cap	53.91M
Revenue (ttm)	n/a
Net Income (ttm)	-46.84M
Shares Out	10.76M
EPS (ttm)	-4.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,396
Open	5.20
Previous Close	5.06
Day's Range	4.90 - 5.20
52-Week Range	2.96 - 11.45
Beta	n/a
Analysts	Strong Buy
Price Target	9.50 (+89.62%)
Earnings Date	Nov 13, 2024

About ELTX

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: ELTX
• Website: https://elicio.com

Analyst Forecast

According to 3 analysts, the average rating for ELTX stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 89.62% from the latest price.

Price Target

$9.5

(89.62% upside)

Analyst Consensus: Strong Buy